These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26967009)

  • 21. Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment.
    Chimenti MS; Perricone C; Graceffa D; Di Muzio G; Ballanti E; Guarino MD; Conigliaro P; Greco E; Kroegler B; Perricone R
    Clin Exp Rheumatol; 2012; 30(1):23-30. PubMed ID: 22260811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two.
    Moro ML; Nobilio L; Voci C; Di Mario S; Candela S; Magrini N;
    Vaccine; 2013 Feb; 31(10):1438-46. PubMed ID: 22885015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
    Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
    Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations.
    Van den Bosch F; Kavanaugh A; Kron M; Kupper H; Mease PJ
    J Rheumatol; 2015 Jun; 42(6):952-9. PubMed ID: 25834212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis.
    Toplak N; Subelj V; Kveder T; Cucnik S; Prosenc K; Trampus-Bakija A; Todorovski L; Avcin T
    Clin Exp Rheumatol; 2012; 30(3):436-44. PubMed ID: 22513085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers.
    Di Minno MN; Iervolino S; Peluso R; Russolillo A; Lupoli R; Scarpa R; Di Minno G; Tarantino G;
    J Rheumatol; 2012 May; 39(5):1042-6. PubMed ID: 22422493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
    Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
    Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease.
    Perdan-Pirkmajer K; Thallinger GG; Snoj N; Čučnik S; Žigon P; Kveder T; Logar D; Praprotnik S; Tomšič M; Sodin-Semrl S; Ambrožič A
    Lupus; 2012 Feb; 21(2):175-83. PubMed ID: 22235050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis.
    Haddad A; Thavaneswaran A; Ruiz-Arruza I; Pellett F; Chandran V; Cook RJ; Gladman DD
    Arthritis Care Res (Hoboken); 2015 May; 67(6):842-7. PubMed ID: 25469741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
    Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of mud-bath therapy in psoriatic arthritis patients treated with TNF inhibitors. Clinical evaluation and assessment of synovial inflammation by contrast-enhanced ultrasound (CEUS).
    Cozzi F; Raffeiner B; Beltrame V; Ciprian L; Coran A; Botsios C; Perissinotto E; Grisan E; Ramonda R; Oliviero F; Stramare R; Punzi L
    Joint Bone Spine; 2015 Mar; 82(2):104-8. PubMed ID: 25623520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept.
    Lubrano E; Spadaro A; Marchesoni A; Olivieri I; Scarpa R; D'Angelo S; Salvarani C; Mathieu A; Cauli A; Ferrara N; Helliwell P
    Clin Exp Rheumatol; 2011; 29(1):80-4. PubMed ID: 21345296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemostatic and fibrinolytic changes are related to inflammatory conditions in patients with psoriatic arthritis--effect of different treatments.
    Di Minno MN; Iervolino S; Peluso R; Di Minno A; Ambrosino P; Scarpa R;
    J Rheumatol; 2014 Apr; 41(4):714-22. PubMed ID: 24532831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study.
    Carraro G; Naso A; Montomoli E; Gasparini R; Camerini R; Panatto D; Tineo MC; De Giorgi L; Piccirella S; Khadang B; Ceracchi M; De Rosa A
    Vaccine; 2012 Feb; 30(6):1170-80. PubMed ID: 22178096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a preliminary US power Doppler composite score for monitoring treatment in PsA.
    Gutierrez M; Di Geso L; Salaffi F; Bertolazzi C; Tardella M; Filosa G; Filippucci E; Grassi W
    Rheumatology (Oxford); 2012 Jul; 51(7):1261-8. PubMed ID: 22378715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis.
    Allard A; Antony A; Shaddick G; Jadon DR; Cavill C; Robinson G; Korendowych E; McHugh N; Tillett W
    Rheumatology (Oxford); 2019 Feb; 58(2):269-273. PubMed ID: 30247726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination.
    Gelinck LB; van der Bijl AE; Beyer WE; Visser LG; Huizinga TW; van Hogezand RA; Rimmelzwaan GF; Kroon FP
    Ann Rheum Dis; 2008 May; 67(5):713-6. PubMed ID: 17965123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D
    J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.